
|Videos|October 7, 2016
Scrutiny of High Drug Costs Require Specialty Pharmacy Strategy Shift
Author(s)Lauren Santye, Assistant Editor
Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how specialty pharmacies may need to alter current strategies with increasing attention on high drug costs.
Advertisement
Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how specialty pharmacies may need to alter current strategies with increasing attention on high drug costs.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Abemaciclib Provides Long-Term Survival Benefit in High-Risk Early Breast Cancer
2
Five-Year NATALEE Data Show Ribociclib Improves Outcomes in High-Risk HR+/HER2– Early Breast Cancer
3
Durvalumab Plus Chemotherapy Sets New Standard in Resectable Gastric and GEJ Cancer
4
TAR-200 Intravesical System Demonstrates Sustained Bladder Exposure in BCG-Unresponsive NMIBC
5